Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Heartflow, Inc.HTFL · Entity 3993 | Chief Accounting Officer | March 06, 2026 | August 10, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Heartflow, Inc.
Report date March 06, 2026 · Filed August 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock.SEC Table I · non-derivative | Direct | 33,311 |
Reported balance
After 2026-03-06 transaction · row 1
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 1 · 2026-03-06 · Grant · Acquired 1,661 · Balance 33,311 F1: These shares were acquired under the Issuer's Employee Stock Purchase Plan in a transaction exempt under Rule 16b-3(c).? The share balance reflects the Reporting Person's total current holdings immediately following the reported transaction. |
| Common Stock.SEC Table I · non-derivative | Direct | 32,258 |
Reported balance
After 2026-08-06 transaction · row 2
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 2 · 2026-08-06 · Tax withholding · Disposed 486 · Balance 32,258 F2: Represents shares that have been retained by the Issuer to satisfy income tax withholding and remittance obligations in connection with the vesting and net settlement of restricted stock units previously reported. |
| Common Stock.SEC Table I · non-derivative | Direct | 32,176 |
Reported balance
After 2026-08-07 transaction · row 3
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 3 · 2026-08-07 · Tax withholding · Disposed 82 · Balance 32,176 F2: Represents shares that have been retained by the Issuer to satisfy income tax withholding and remittance obligations in connection with the vesting and net settlement of restricted stock units previously reported. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares were acquired under the Issuer's Employee Stock Purchase Plan in a transaction exempt under Rule 16b-3(c).? The share balance reflects the Reporting Person's total current holdings immediately following the reported transaction.
F2: Represents shares that have been retained by the Issuer to satisfy income tax withholding and remittance obligations in connection with the vesting and net settlement of restricted stock units previously reported.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Silk Road Medical Inc
Report date September 17, 2024 · Filed September 18, 2024
Section 16 reporting ended · disclosed 2024-09-18. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2024-09-17 transaction · row 1
1 source rowRow 1 · 2024-09-17 · Disposition to issuer · Disposed 79,266 · Balance 0 F1: Of the reported shares, 49,414 are represented by restricted stock units, or RSUs, each of which represents a contingent right to receive one share of Issuer common stock. F2: Includes 2,000 shares and 372 shares acquired under the Issuer's 2019 Employee Stock Purchase Plan on May 20, 2024 and September 13, 2024, respectively. F3: Pursuant to the Agreement and Plan of Merger dated June 17, 2024, between the Issuer, Boston Scientific Corporation and Seminole Merger Sub, Inc, (the "Merger Agreement"), each share of Issuer common stock was canceled and converted into the right to receive $27.50 per share in cash (the "Merger Consideration"), without interest and subject to applicable withholding taxes. F4: Pursuant to the Merger Agreement, each RSU was canceled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the Merger Consideration and (ii) the aggregate number of shares underlying the RSUs, less applicable taxes and authorized deductions. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.11 · Expires 2028-03-22 | Direct | 0 |
Reported balance
After 2024-09-17 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-09-17 · Disposition to issuer · Disposed 71,661 · Balance 0 F5: The shares subject to the option are fully vested and immediately exercisable. Pursuant to the Merger Agreement, the option was cancelled in exchange for a cash payment of $1,532,828.79 which represents the difference between (i) the amount by which the Merger Consideration exceeded the exercise price of the option per share option and (ii) the aggregate number of shares remaining issuable upon exercise of the option, less applicable taxes and authorized deductions. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.11 · Expires 2028-09-23 | Direct | 0 |
Reported balance
After 2024-09-17 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-09-17 · Disposition to issuer · Disposed 16,518 · Balance 0 F6: The shares subject to the option are fully vested and immediately exercisable. Pursuant to the Merger Agreement, the option was cancelled in exchange for a cash payment of $353,320.02, which represents the difference between (i) the amount by which the Merger Consideration exceeded the exercise price of the option per share option and (ii) the aggregate number of shares remaining issuable upon exercise of the option, less applicable taxes and authorized deductions. |
Filing footnotes · ownership attribution and instrument terms
F1: Of the reported shares, 49,414 are represented by restricted stock units, or RSUs, each of which represents a contingent right to receive one share of Issuer common stock.
F2: Includes 2,000 shares and 372 shares acquired under the Issuer's 2019 Employee Stock Purchase Plan on May 20, 2024 and September 13, 2024, respectively.
F3: Pursuant to the Agreement and Plan of Merger dated June 17, 2024, between the Issuer, Boston Scientific Corporation and Seminole Merger Sub, Inc, (the "Merger Agreement"), each share of Issuer common stock was canceled and converted into the right to receive $27.50 per share in cash (the "Merger Consideration"), without interest and subject to applicable withholding taxes.
F4: Pursuant to the Merger Agreement, each RSU was canceled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the Merger Consideration and (ii) the aggregate number of shares underlying the RSUs, less applicable taxes and authorized deductions.
F5: The shares subject to the option are fully vested and immediately exercisable. Pursuant to the Merger Agreement, the option was cancelled in exchange for a cash payment of $1,532,828.79 which represents the difference between (i) the amount by which the Merger Consideration exceeded the exercise price of the option per share option and (ii) the aggregate number of shares remaining issuable upon exercise of the option, less applicable taxes and authorized deductions.
F6: The shares subject to the option are fully vested and immediately exercisable. Pursuant to the Merger Agreement, the option was cancelled in exchange for a cash payment of $353,320.02, which represents the difference between (i) the amount by which the Merger Consideration exceeded the exercise price of the option per share option and (ii) the aggregate number of shares remaining issuable upon exercise of the option, less applicable taxes and authorized deductions.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 07, 2026 Filed Aug 10, 2026 21:21 UTC | Heartflow, Inc. HTFL · Entity 3993 | Tax withholdingCommon Stock. | 82 | $28.82 | $2,363.24 |
DisclosureSEC source: 0001464521-26-000123 · form4.xml · nonDerivative · entry 3 Jones Marie L. · CIK 0001968991 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,176 F2 · shares: Represents shares that have been retained by the Issuer to satisfy income tax withholding and remittance obligations in connection with the vesting and net settlement of restricted stock units previously reported. Read SEC document |
| August 06, 2026 Filed Aug 10, 2026 21:21 UTC | Heartflow, Inc. HTFL · Entity 3993 | Tax withholdingCommon Stock. | 486 | $27.19 | $13,214.34 |
DisclosureSEC source: 0001464521-26-000123 · form4.xml · nonDerivative · entry 2 Jones Marie L. · CIK 0001968991 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,258 F2 · shares: Represents shares that have been retained by the Issuer to satisfy income tax withholding and remittance obligations in connection with the vesting and net settlement of restricted stock units previously reported. Read SEC document |
| May 07, 2026 Filed May 8, 2026 22:47 UTC | Heartflow, Inc. HTFL · Entity 3993 | Tax withholdingCommon Stock. | 82 | $29.98 | $2,458.36 |
DisclosureSEC source: 0001464521-26-000063 · form4.xml · nonDerivative · entry 2 Jones Marie L. · CIK 0001968991 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,083 F1 · shares: Represents shares that have been retained by the Issuer to satisfy income tax withholding and remittance obligations in connection with the vesting and net settlement of restricted stock units previously reported. Read SEC document |
| May 06, 2026 Filed May 8, 2026 22:47 UTC | Heartflow, Inc. HTFL · Entity 3993 | Tax withholdingCommon Stock. | 485 | $30.29 | $14,690.65 |
DisclosureSEC source: 0001464521-26-000063 · form4.xml · nonDerivative · entry 1 Jones Marie L. · CIK 0001968991 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,165 F1 · shares: Represents shares that have been retained by the Issuer to satisfy income tax withholding and remittance obligations in connection with the vesting and net settlement of restricted stock units previously reported. Read SEC document |
| March 06, 2026 Filed Aug 10, 2026 21:21 UTC | Heartflow, Inc. HTFL · Entity 3993 | GrantCommon Stock. | 1,661 | $16.15 | $26,825.15 |
DisclosureSEC source: 0001464521-26-000123 · form4.xml · nonDerivative · entry 1 Jones Marie L. · CIK 0001968991 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,311 F1 · kind: These shares were acquired under the Issuer's Employee Stock Purchase Plan in a transaction exempt under Rule 16b-3(c).? The share balance reflects the Reporting Person's total current holdings immediately following the reported transaction. Read SEC document |
| February 06, 2026 Filed Feb 11, 2026 01:55 UTC | Heartflow, Inc. HTFL · Entity 3993 | GrantStock Option · Derivative | 37,795 | $0.00 Strike: $27.74 | $0.00 |
DisclosureSEC source: 0001464521-26-000016 · form4.xml · derivative · entry 3 Jones Marie L. · CIK 0001968991 · Chief Accounting Officer, VP 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,795 Underlying: Common Stock · 37,795 shares Expires 2036-02-06 F3 · derivative.exercise_date: The option vests 1/48 on each monthly anniversary of the Vesting Commencement Date, subject to continued service through the applicable vesting date. Read SEC document |
| February 06, 2026 Filed Feb 11, 2026 01:55 UTC | Heartflow, Inc. HTFL · Entity 3993 | GrantCommon Stock. | 21,629 | $0.00 | $0.00 |
DisclosureSEC source: 0001464521-26-000016 · form4.xml · nonDerivative · entry 2 Jones Marie L. · CIK 0001968991 · Chief Accounting Officer, VP 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,650 F2 · shares: Represents restricted stock units ("RSUs"), with a vesting commencement date of February 6, 2026 (the "Vesting Commencement Date"). 1/16th of the RSUs vest on each quarterly anniversary of the Vesting Commencement Date, subject to continued service through the applicable vesting date. Read SEC document |
| February 06, 2026 Filed Feb 11, 2026 01:55 UTC | Heartflow, Inc. HTFL · Entity 3993 | Tax withholdingCommon Stock. | 94 | $27.74 | $2,607.56 |
DisclosureSEC source: 0001464521-26-000016 · form4.xml · nonDerivative · entry 1 Jones Marie L. · CIK 0001968991 · Chief Accounting Officer, VP 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,021 F1 · shares: Represents shares that have been retained by the Issuer to satisfy income tax withholding and remittance obligations in connection with the vesting and net settlement of restricted stock units previously reported. Read SEC document |
| November 07, 2025 Filed Nov 13, 2025 01:34 UTC | Heartflow, Inc. HTFL · Entity 3993 | Tax withholdingCommon Stock. | 81 | $32.56 | $2,637.36 |
DisclosureSEC source: 0001464521-25-000027 · form4.xml · nonDerivative · entry 1 Jones Marie L. · CIK 0001968991 · Chief Accounting Officer, VP 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,115 F1 · shares: Represents shares that have been retained by the Issuer to satisfy income tax withholding and remittance obligations in connection with the vesting and net settlement of restricted stock units previously reported. Read SEC document |
| August 11, 2025 Filed Aug 12, 2025 01:00 UTC | Heartflow, Inc. HTFL · Entity 3993 | ConversionConvertible Promissory Note · Derivative | 6,578 | $0.00 Strike: $15.20 | $0.00 |
DisclosureSEC source: 0001628280-25-039732 · wk-form4_1754960452.xml · derivative · entry 5 Jones Marie L. · CIK 0001968991 · Chief Accounting Officer, VP 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,578 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · shares: Upon the closing of Heartflow, Inc.'s ("Heartflow") initial public offering, the convertible promissory notes automatically converted into shares of Heartflow's common stock at a conversion price of 80% of the price per share in Heartflow's initial public offering, subject to a valuation ceiling of $2.0 billion. The shares of Heartflow's common stock that were issuable upon conversion of the convertible promissory note had no expiration date. These shares are reported in Table II above on an as-converted basis. F2 · derivative.exercise_date: Upon the closing of Heartflow, Inc.'s ("Heartflow") initial public offering, the convertible promissory notes automatically converted into shares of Heartflow's common stock at a conversion price of 80% of the price per share in Heartflow's initial public offering, subject to a valuation ceiling of $2.0 billion. The shares of Heartflow's common stock that were issuable upon conversion of the convertible promissory note had no expiration date. These shares are reported in Table II above on an as-converted basis. F2 · derivative.expiration_date: Upon the closing of Heartflow, Inc.'s ("Heartflow") initial public offering, the convertible promissory notes automatically converted into shares of Heartflow's common stock at a conversion price of 80% of the price per share in Heartflow's initial public offering, subject to a valuation ceiling of $2.0 billion. The shares of Heartflow's common stock that were issuable upon conversion of the convertible promissory note had no expiration date. These shares are reported in Table II above on an as-converted basis. Read SEC document |
| August 11, 2025 Filed Aug 12, 2025 01:00 UTC | Heartflow, Inc. HTFL · Entity 3993 | ConversionCommon Stock. | 6,578 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-25-039732 · wk-form4_1754960452.xml · nonDerivative · entry 2 Jones Marie L. · CIK 0001968991 · Chief Accounting Officer, VP 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,196 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Upon the closing of Heartflow, Inc.'s ("Heartflow") initial public offering, the convertible promissory notes automatically converted into shares of Heartflow's common stock at a conversion price of 80% of the price per share in Heartflow's initial public offering, subject to a valuation ceiling of $2.0 billion. The shares of Heartflow's common stock that were issuable upon conversion of the convertible promissory note had no expiration date. These shares are reported in Table II above on an as-converted basis. Read SEC document |
| August 07, 2025 Filed Aug 12, 2025 01:00 UTC | Heartflow, Inc. HTFL · Entity 3993 | GrantStock Option · Derivative | 19,014 | $0.00 Strike: $19.00 | $0.00 |
DisclosureSEC source: 0001628280-25-039732 · wk-form4_1754960452.xml · derivative · entry 4 Jones Marie L. · CIK 0001968991 · Chief Accounting Officer, VP 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,014 Underlying: Common Stock · 19,014 shares Expires 2035-08-07 F4 · derivative.exercise_date: The option vests 1/48 on each monthly anniversary of the Vesting Commencement Date, subject to continued service through the applicable vesting date. Read SEC document |
| August 07, 2025 Filed Aug 12, 2025 01:00 UTC | Heartflow, Inc. HTFL · Entity 3993 | GrantCommon Stock | 3,618 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-039732 · wk-form4_1754960452.xml · nonDerivative · entry 1 Jones Marie L. · CIK 0001968991 · Chief Accounting Officer, VP 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,618 F1 · shares: Represents restricted stock units ("RSUs"), with a vesting commencement date of August 7, 2025 (the "Vesting Commencement Date"). 1/16th of the RSUs vest on each quarterly anniversary of the Vesting Commencement Date, subject to continued service through the applicable vesting date. Read SEC document |
| March 13, 2025 Filed Aug 12, 2025 01:00 UTC | Heartflow, Inc. HTFL · Entity 3993 | GrantStock Option · Derivative | 68,492 | $0.00 Strike: $12.68 | $0.00 |
DisclosureSEC source: 0001628280-25-039732 · wk-form4_1754960452.xml · derivative · entry 3 Jones Marie L. · CIK 0001968991 · Chief Accounting Officer, VP 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 68,492 Underlying: Common Stock · 68,492 shares Expires 2035-03-13 F3 · derivative.exercise_date: 1/4th of the options will vest on January 8, 2026, and the remaining shares will vest and become exercisable in monthly installments until January 8, 2029, subject to continued service through the applicable vesting date. Read SEC document |
| September 17, 2024 Filed Sep 18, 2024 20:35 UTC | Silk Road Medical Inc SILK · Entity 87417 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 16,518 | $21.39 Strike: $6.11 | $353,320.02 |
DisclosureSEC source: 0001140361-24-041414 · form4.xml · derivative · entry 3 Jones Marie L. · CIK 0001968991 · VP, Finance and CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,518 shares Expires 2028-09-23 F6 · derivative.exercise_date: The shares subject to the option are fully vested and immediately exercisable. Pursuant to the Merger Agreement, the option was cancelled in exchange for a cash payment of $353,320.02, which represents the difference between (i) the amount by which the Merger Consideration exceeded the exercise price of the option per share option and (ii) the aggregate number of shares remaining issuable upon exercise of the option, less applicable taxes and authorized deductions. Read SEC document |
| September 17, 2024 Filed Sep 18, 2024 20:35 UTC | Silk Road Medical Inc SILK · Entity 87417 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 71,661 | $21.39 Strike: $6.11 | $1,532,828.79 |
DisclosureSEC source: 0001140361-24-041414 · form4.xml · derivative · entry 2 Jones Marie L. · CIK 0001968991 · VP, Finance and CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 71,661 shares Expires 2028-03-22 F5 · derivative.exercise_date: The shares subject to the option are fully vested and immediately exercisable. Pursuant to the Merger Agreement, the option was cancelled in exchange for a cash payment of $1,532,828.79 which represents the difference between (i) the amount by which the Merger Consideration exceeded the exercise price of the option per share option and (ii) the aggregate number of shares remaining issuable upon exercise of the option, less applicable taxes and authorized deductions. Read SEC document |
| September 17, 2024 Filed Sep 18, 2024 20:35 UTC | Silk Road Medical Inc SILK · Entity 87417 | Disposition to issuerCommon Stock | 79,266 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-24-041414 · form4.xml · nonDerivative · entry 1 Jones Marie L. · CIK 0001968991 · VP, Finance and CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · shares: Of the reported shares, 49,414 are represented by restricted stock units, or RSUs, each of which represents a contingent right to receive one share of Issuer common stock. F2 · shares: Includes 2,000 shares and 372 shares acquired under the Issuer's 2019 Employee Stock Purchase Plan on May 20, 2024 and September 13, 2024, respectively. F3 · price: Pursuant to the Agreement and Plan of Merger dated June 17, 2024, between the Issuer, Boston Scientific Corporation and Seminole Merger Sub, Inc, (the "Merger Agreement"), each share of Issuer common stock was canceled and converted into the right to receive $27.50 per share in cash (the "Merger Consideration"), without interest and subject to applicable withholding taxes. F4 · price: Pursuant to the Merger Agreement, each RSU was canceled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the Merger Consideration and (ii) the aggregate number of shares underlying the RSUs, less applicable taxes and authorized deductions. Read SEC document |
| March 05, 2024 Filed Mar 5, 2024 18:20 UTC | Silk Road Medical Inc SILK · Entity 87417 | SaleCommon Stock | 2,602 | $17.17 | $44,673.74 |
DisclosureSEC source: 0001593968-24-000433 · primary_01.xml · nonDerivative · entry 2 Jones Marie L. · CIK 0001968991 · VP, Finance and CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 76,894 F2 · shares: Represents shares that have been sold by the Reporting Person to satisfy income tax withholding and remittance obligations in connection with the vesting and net settlement of restricted stock units previously reported. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 18:20 UTC | Silk Road Medical Inc SILK · Entity 87417 | GrantCommon Stock | 24,555 | $0.00 | $0.00 |
DisclosureSEC source: 0001593968-24-000433 · primary_01.xml · nonDerivative · entry 1 Jones Marie L. · CIK 0001968991 · VP, Finance and CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 79,496 F1 · shares: The reported securities are represented by restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of SILK common stock. 25% of the shares shall vest on March 1, 2025 and each one-year anniversary thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| October 27, 2023 Filed Oct 30, 2023 18:53 UTC | Silk Road Medical Inc SILK · Entity 87417 | SaleCommon Stock | 656 | $6.61 | $4,334.19 |
DisclosureSEC source: 0001593968-23-001378 · primary_01.xml · nonDerivative · entry 1 Jones Marie L. · CIK 0001968991 · CAO and VP, Finance 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,941 F1 · shares: Represents shares that have been sold by the Reporting Person to satisfy income tax withholding and remittance obligations in connection with the vesting and net settlement of restricted stock units previously reported. Read SEC document |
| September 15, 2023 Filed Sep 15, 2023 19:04 UTC | Silk Road Medical Inc SILK · Entity 87417 | GrantCommon Stock | 7,595 | $0.00 | $0.00 |
DisclosureSEC source: 0001593968-23-001326 · primary_01.xml · nonDerivative · entry 1 Jones Marie L. · CIK 0001968991 · CAO and VP, Finance 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,597 F1 · shares: The reported securities are represented by restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of SILK common stock. 25% of the shares shall vest on September 15, 2024 and each one-year anniversary thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| July 20, 2023 Filed Jul 21, 2023 18:24 UTC | Silk Road Medical Inc SILK · Entity 87417 | Exercise / conversionOption (right to buy) · Derivative | 2,000 | $0.00 Strike: $6.11 | $0.00 |
DisclosureSEC source: 0001593968-23-001133 · primary_01.xml · derivative · entry 3 Jones Marie L. · CIK 0001968991 · CAO and VP, Finance 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,031 Underlying: Common Stock · 2,000 shares Expires 2028-09-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: All of the shares subject to the option are fully vested and exercisable as of the date hereof. Read SEC document |
| July 20, 2023 Filed Jul 21, 2023 18:24 UTC | Silk Road Medical Inc SILK · Entity 87417 | Exercise / conversionCommon Stock | 2,000 | $6.11 | $12,220.00 |
DisclosureSEC source: 0001593968-23-001133 · primary_01.xml · nonDerivative · entry 2 Jones Marie L. · CIK 0001968991 · CAO and VP, Finance 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,002 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 19, 2023 Filed Jul 21, 2023 18:24 UTC | Silk Road Medical Inc SILK · Entity 87417 | GrantCommon Stock | 506 | $26.17 | $13,242.02 |
DisclosureSEC source: 0001593968-23-001133 · primary_01.xml · nonDerivative · entry 1 Jones Marie L. · CIK 0001968991 · CAO and VP, Finance 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,002 F1 · kind: These shares were acquired under the Issuer's Employee Stock Purchase Plan in a transaction exempt under Rule 16b-3(c). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.